These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

566 related articles for article (PubMed ID: 32042196)

  • 1. Peripheral CD8
    Fairfax BP; Taylor CA; Watson RA; Nassiri I; Danielli S; Fang H; Mahé EA; Cooper R; Woodcock V; Traill Z; Al-Mossawi MH; Knight JC; Klenerman P; Payne M; Middleton MR
    Nat Med; 2020 Feb; 26(2):193-199. PubMed ID: 32042196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination anti-PD-1 and anti-CTLA-4 therapy generates waves of clonal responses that include progenitor-exhausted CD8
    Wang K; Coutifaris P; Brocks D; Wang G; Azar T; Solis S; Nandi A; Anderson S; Han N; Manne S; Kiner E; Sachar C; Lucas M; George S; Yan PK; Kier MW; Laughlin AI; Kothari S; Giles J; Mathew D; Ghinnagow R; Alanio C; Flowers A; Xu W; Tenney DJ; Xu X; Amaravadi RK; Karakousis GC; Schuchter LM; Buggert M; Oldridge D; Minn AJ; Blank C; Weber JS; Mitchell TC; Farwell MD; Herati RS; Huang AC
    Cancer Cell; 2024 Sep; 42(9):1582-1597.e10. PubMed ID: 39214097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clonality of CD4
    Arakawa A; Vollmer S; Tietze J; Galinski A; Heppt MV; Bürdek M; Berking C; Prinz JC
    Front Immunol; 2019; 10():1336. PubMed ID: 31275310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single-cell analysis of peripheral CD8
    Khojandi N; Connelly L; Piening A; Hoft SG; Pherson M; Donlin MJ; DiPaolo RJ; Teague RM
    Cancer Immunol Immunother; 2023 Feb; 72(2):397-408. PubMed ID: 35907015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade.
    Wei SC; Levine JH; Cogdill AP; Zhao Y; Anang NAS; Andrews MC; Sharma P; Wang J; Wargo JA; Pe'er D; Allison JP
    Cell; 2017 Sep; 170(6):1120-1133.e17. PubMed ID: 28803728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential effects of PD-1 and CTLA-4 blockade on the melanoma-reactive CD8 T cell response.
    Gangaev A; Rozeman EA; Rohaan MW; Isaeva OI; Philips D; Patiwael S; van den Berg JH; Ribas A; Schadendorf D; Schilling B; Schumacher TN; Blank CU; Haanen JBAG; Kvistborg P
    Proc Natl Acad Sci U S A; 2021 Oct; 118(43):. PubMed ID: 34670835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T cell receptor sequencing of activated CD8 T cells in the blood identifies tumor-infiltrating clones that expand after PD-1 therapy and radiation in a melanoma patient.
    Wieland A; Kamphorst AO; Adsay NV; Masor JJ; Sarmiento J; Nasti TH; Darko S; Douek DC; Xue Y; Curran WJ; Lawson DH; Ahmed R
    Cancer Immunol Immunother; 2018 Nov; 67(11):1767-1776. PubMed ID: 30167863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies.
    Wei SC; Anang NAS; Sharma R; Andrews MC; Reuben A; Levine JH; Cogdill AP; Mancuso JJ; Wargo JA; Pe'er D; Allison JP
    Proc Natl Acad Sci U S A; 2019 Nov; 116(45):22699-22709. PubMed ID: 31636208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy.
    Luoma AM; Suo S; Williams HL; Sharova T; Sullivan K; Manos M; Bowling P; Hodi FS; Rahma O; Sullivan RJ; Boland GM; Nowak JA; Dougan SK; Dougan M; Yuan GC; Wucherpfennig KW
    Cell; 2020 Aug; 182(3):655-671.e22. PubMed ID: 32603654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma.
    Daud AI; Loo K; Pauli ML; Sanchez-Rodriguez R; Sandoval PM; Taravati K; Tsai K; Nosrati A; Nardo L; Alvarado MD; Algazi AP; Pampaloni MH; Lobach IV; Hwang J; Pierce RH; Gratz IK; Krummel MF; Rosenblum MD
    J Clin Invest; 2016 Sep; 126(9):3447-52. PubMed ID: 27525433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improvement of PD-1 Blockade Efficacy and Elimination of Immune-Related Gastrointestinal Adverse Effect by mTOR Inhibitor.
    Bai X; Wang X; Ma G; Song J; Liu X; Wu X; Zhao Y; Liu X; Liu Z; Zhang W; Zhao X; Zheng Z; Jing J; Shi H
    Front Immunol; 2021; 12():793831. PubMed ID: 34987517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TCR Repertoire Diversity of Peripheral PD-1
    Han J; Duan J; Bai H; Wang Y; Wan R; Wang X; Chen S; Tian Y; Wang D; Fei K; Yao Z; Wang S; Lu Z; Wang Z; Wang J
    Cancer Immunol Res; 2020 Jan; 8(1):146-154. PubMed ID: 31719056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CTLA-4 blockade increases antigen-specific CD8(+) T cells in prevaccinated patients with melanoma: three cases.
    Yuan J; Ginsberg B; Page D; Li Y; Rasalan T; Gallardo HF; Xu Y; Adams S; Bhardwaj N; Busam K; Old LJ; Allison JP; Jungbluth A; Wolchok JD
    Cancer Immunol Immunother; 2011 Aug; 60(8):1137-46. PubMed ID: 21465316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade.
    Andrews MC; Duong CPM; Gopalakrishnan V; Iebba V; Chen WS; Derosa L; Khan MAW; Cogdill AP; White MG; Wong MC; Ferrere G; Fluckiger A; Roberti MP; Opolon P; Alou MT; Yonekura S; Roh W; Spencer CN; Curbelo IF; Vence L; Reuben A; Johnson S; Arora R; Morad G; Lastrapes M; Baruch EN; Little L; Gumbs C; Cooper ZA; Prieto PA; Wani K; Lazar AJ; Tetzlaff MT; Hudgens CW; Callahan MK; Adamow M; Postow MA; Ariyan CE; Gaudreau PO; Nezi L; Raoult D; Mihalcioiu C; Elkrief A; Pezo RC; Haydu LE; Simon JM; Tawbi HA; McQuade J; Hwu P; Hwu WJ; Amaria RN; Burton EM; Woodman SE; Watowich S; Diab A; Patel SP; Glitza IC; Wong MK; Zhao L; Zhang J; Ajami NJ; Petrosino J; Jenq RR; Davies MA; Gershenwald JE; Futreal PA; Sharma P; Allison JP; Routy B; Zitvogel L; Wargo JA
    Nat Med; 2021 Aug; 27(8):1432-1441. PubMed ID: 34239137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD-1 blockade induces responses by inhibiting adaptive immune resistance.
    Tumeh PC; Harview CL; Yearley JH; Shintaku IP; Taylor EJ; Robert L; Chmielowski B; Spasic M; Henry G; Ciobanu V; West AN; Carmona M; Kivork C; Seja E; Cherry G; Gutierrez AJ; Grogan TR; Mateus C; Tomasic G; Glaspy JA; Emerson RO; Robins H; Pierce RH; Elashoff DA; Robert C; Ribas A
    Nature; 2014 Nov; 515(7528):568-71. PubMed ID: 25428505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy.
    Chowell D; Morris LGT; Grigg CM; Weber JK; Samstein RM; Makarov V; Kuo F; Kendall SM; Requena D; Riaz N; Greenbaum B; Carroll J; Garon E; Hyman DM; Zehir A; Solit D; Berger M; Zhou R; Rizvi NA; Chan TA
    Science; 2018 Feb; 359(6375):582-587. PubMed ID: 29217585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit.
    Yuan J; Gnjatic S; Li H; Powel S; Gallardo HF; Ritter E; Ku GY; Jungbluth AA; Segal NH; Rasalan TS; Manukian G; Xu Y; Roman RA; Terzulli SL; Heywood M; Pogoriler E; Ritter G; Old LJ; Allison JP; Wolchok JD
    Proc Natl Acad Sci U S A; 2008 Dec; 105(51):20410-5. PubMed ID: 19074257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessing clonal changes in T cells over time following immunotherapy is a breeze with Cyclone.
    Cillo AR; Kirkwood JM
    Cancer Cell; 2024 Sep; 42(9):1491-1493. PubMed ID: 39255774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes of peripheral T cell subsets in melanoma patients with immune-related adverse events.
    Müller B; Bärenwaldt A; Herzig P; Zippelius A; Maul LV; Hess V; König D; Läubli H
    Front Immunol; 2023; 14():1125111. PubMed ID: 37122748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade.
    House IG; Savas P; Lai J; Chen AXY; Oliver AJ; Teo ZL; Todd KL; Henderson MA; Giuffrida L; Petley EV; Sek K; Mardiana S; Gide TN; Quek C; Scolyer RA; Long GV; Wilmott JS; Loi S; Darcy PK; Beavis PA
    Clin Cancer Res; 2020 Jan; 26(2):487-504. PubMed ID: 31636098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.